Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Interest in nanoneuromedicine has grown rapidly due to the immediate need for improved biomarkers and therapies for psychiatric, developmental, traumatic, inflammatory, infectious and degenerative nervous system disorders. These, in whole or in part, are a significant societal burden due to growth in numbers of affected people and in disease severity. Lost productivity of the patient and his or her caregiver, and the emotional and financial burden cannot be overstated. The need for improved health care, treatment and diagnostics is immediate. A means to such an end is nanotechnology. Indeed, recent developments of health-care enabling nanotechnologies and nanomedicines range from biomarker discovery including neuroimaging to therapeutic applications for degenerative, inflammatory and infectious disorders of the nervous system. This review focuses on the current and future potential of the field to positively affect clinical outcomes. From the clinical editor: Many nervous system disorders remain unresolved clinical problems. In many cases, drug agents simply cannot cross the blood-brain barrier (BBB) into the nervous system. The advent of nanomedicines can enhance the delivery of biologically active molecules for targeted therapy and imaging. This review focused on the use of nanotechnology for degenerative, inflammatory, and infectious diseases in the nervous system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Laurent, S., Forge, D., Port, M., Roch, A., Robic, C., Vander Elst, L., & Muller, R. N. (2008) · Chemical Reviews · doi:10.1021/cr068445e · Cited by 6,852 · cited 1×
“Biocompatible SPIO nanoparticles consist of a crystalline iron oxide core (in the form of magnetite, Fe3O4, or maghemite, γFe2O3) encased in polymer or a coated monomer (Figure 1, upper panel).(7,8) The particles can be classified according to their size in several categories: particles with a mean diameter of 50 to 1…”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807
Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835
Solid lipid nanoparticles for targeted brain drug delivery.
BLASI, P., GIOVAGNOLI, S., SCHOUBBEN, A., RICCI, M., & ROSSI, C. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.011 · Cited by 506
Weinstein, J. S., Varallyay, C. G., Dosa, E., Gahramanov, S., Hamilton, B., Rooney, W. D., Muldoon, L. L., & Neuwelt, E. A. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.192 · Cited by 500
In vivo MRI cell tracking: clinical studies
Bulte, J. W. M. (2009) · American Journal of Roentgenology · doi:10.2214/ajr.09.3107 · Cited by 430
Strategy for effective brain drug delivery
Alam, M. I., Beg, S., Samad, A., Baboota, S., Kohli, K., Ali, J., Ahuja, A., & Akbar, M. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.05.003 · Cited by 415
Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles
Kurakhmaeva, K. B., Djindjikhashvili, I. A., Petrov, V. E., Balabanyan, V. U., Voronina, T. A., Trofimov, S. S., Kreuter, J., Gelperina, S., Begley, D., & Alyautdin, R. N. (2009) · Journal of Drug Targeting · doi:10.1080/10611860903112842 · Cited by 221
Neuwelt, E. A., Várallyay, C. G., Manninger, S., Solymosi, D., Haluska, M., Hunt, M. A., Nesbit, G., Stevens, A., Jerosch-Herold, M., Jacobs, P. M., et al. (2007) · Neurosurgery · doi:10.1227/01.neu.0000255350.71700.37 · Cited by 184
Wadghiri, Y. Z., Li, J., Wang, J., Hoang, D. M., Sun, Y., Xu, H., Tsui, W., Li, Y., Boutajangout, A., Wang, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057097 · Cited by 114 · cited 11×
“Kuo and Su demonstrated that stavudine, delavirdine and saquinavir encapsulated in SLNs more readily passed across an artificial BBB compared to unencapsulated drugs.101 In other in vitro studies, Kuo and Ko used the insulin-like peptidomimetic monoclonal antibody, 83-14 MAb, as a targeting moiety to improve penetrati…”
BackgroundInfluentialAzeem, A., Talegaonkar, S., Negi, L. M., Ahmad, F. J., Khar, R. K., & Iqbal, Z. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.10.039 · Cited by 99 · cited 1×
“An oil-based nanocarrier system (nanoemulsion gel) for ropinirole transdermal delivery has shown efficacy in the 6-OHDA-lesioned rat model.(121) While these studies have shown some promise in improving the bioavailability of dopaminergic agonists, more pre-clinical validations are needed before being applied in clinic…”
BackgroundTransferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain.
Soni, V., Kohli, D. V., & Jain, S. K. (2008) · Journal of drug targeting · doi:10.1080/10611860701725381 · Cited by 96
Pillay, S., Pillay, V., Choonara, Y. E., Naidoo, D., Khan, R. A., du Toit, L. C., Ndesendo, V. M. K., Modi, G., Danckwerts, M. P., & Iyuke, S. E. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.08.021 · Cited by 80 · cited 1×
“Using an intracranial nano-enabled scaffold device implantable in the parenchyma of the frontal lobe of the brain, Pillay and colleagues showed that the inclusion of dopamine-loaded cellulose acetate phthalate NPs into a binary cross-linked alginate scaffold facilitated local dopamine delivery in a rat model.(114) Rec…”
Morales-Narváez, E., Montón, H., Fomicheva, A., & Merkoçi, A. (2012) · Analytical Chemistry · doi:10.1021/ac301369e · Cited by 79 · cited 4×
“Recently, core-shell CdSe/ZnS QDs were used in an assay designed to detect apolipoprotein E (ApoE) as a potential biomarker for AD.(73) The QDs proved to be highly effective reporters and exhibited up to a 7-fold enhancement in limit of detection compared to a conventional enzyme-linked immunosorbent assay targeting A…”
MethodInfluential
Cited by
Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles
Foroozandeh, P., & Aziz, A. A. (2018) · Nanoscale Research Letters · doi:10.1186/s11671-018-2728-6 · Cited by 1,377
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Neuroinflammation pathways: a general review
Shabab, T., Khanabdali, R., Moghadamtousi, S. Z., Kadir, H. A., & Mohan, G. (2017) · International Journal of Neuroscience · doi:10.1080/00207454.2016.1212854 · Cited by 632
A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems
Duan, Y., Dhar, A., Patel, C., Khimani, M., Neogi, S., Sharma, P., Siva Kumar, N., & Vekariya, R. L. (2020) · RSC Advances · doi:10.1039/d0ra03491f · Cited by 614
Richardson, J. R., Fitsanakis, V., Westerink, R. H. S., & Kanthasamy, A. G. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02033-9 · Cited by 539
Self-citation
Metadata
- Authors
- Gendelman, H. E., Anantharam, V., Bronich, T., Ghaisas, S., Jin, H., Kanthasamy, A. G., Liu, X., McMillan, J., Mosley, R. L., Narasimhan, B., & Mallapragada, S. K.
- Venue
- Nanomedicine: Nanotechnology, Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 11
- Issue
- 3
- Pages
- 751-767
- ISSN
- 1549-9634 (ISSN-L)
- OpenAlex
- W2063347334
- Cited by
- 117
- References
- 15
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.